Professor Therese Kinsella, founder and CEO of ATXA Therapeutics, has been named the recipient of the 2024 NovaUCD Innovation Award....

ATXA Therapeutics have today published a new paper in Frontiers in Pharmacology detailing results of its lead drug candidate NTP42 in a...

ATXA Therapeutics will be attending the 23rd Bio€quity Europe Conference, due to be held from May 14 – 16, 2023, in Dublin’s Convention...

ATXA will present data from a First-in-Human (FIH) Phase I trial of NTP42:KVA4, a novel formulation of its lead clinical candidate NTP42...

ATXA Therapeutics have today published a new paper detailing results of its lead drug candidate NTP42 in preclinical models of pulmonary...

ATXA Therapeutics Limited (ATXA) is delighted to announce that it is honoured to receive grant and equity funding through the prestigious...

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for the treatment of pulmonary arterial hypertension (PAH)...

The EU Commission has published a "Results in Brief" article on ATXA Therapeutics' EU-funded PAH-HOPE project. Entitled "New Hope for...

ATXA presented preclinical efficacy results of its lead drug candidate NTP42 for treatment of PAH at the European Society of Cardiology...

ATXA Therapeutics have published a new paper detailing results of its lead drug candidate NTP42 in a further preclinical model of...

Well done to the ATXA Team, who gave a presentation at the World Orphan Drug Virtual Conference on Monday 17th August. They presented on...